Background: Photodynamic therapy (PDT) is a minimally invasive treatment modality for early
Introduction 1
The preferred treatment modalities for early-stage carcinomas and mucosal dysplasia in the 2 oral cavity are surgery and radiotherapy. While both treatment modalities have good cure rates 3 during the early stages 1, 2) , these treatments can lead to functional impairments. Radiotherapy 4 often has irreversible side effects such as endarteritis, xerostomia, and mucositis, along with an 5 added risk for osteoradionecrosis. Similarly, surgery can also have unintended side effects, with 6 both functional and esthetic losses occurring to some degree in other healthy tissues. When 7 present in the oral cavity, there is a potential for mucosal dysplasia to progress to cancer. A 8 previous study has reported that the risk of progression to cancer varies from 6% to 36%.
3) The 9 management of patients with oral dysplasia presents a considerable problem for surgeons, as 10 radiotherapy is not always feasible since it can only be administered once. In addition, this 11 therapy is associated with significant local morbidity. Thus, an optimal treatment for moderate 12 to severe dysplasia of the oral cavity needs to be safe, effective, repeatable, minimally invasive, 13 and devoid of permanent sequelae. Photodynamic therapy (PDT) is a photochemical reaction 14 that is based on the use of a drug, light, and oxygen, with the photochemical reaction leading to 15 a selective destruction of tumor cells. As compared to the other conventional modalities, there 16 are several advantages associated with using the PDT methodology. These include: (1) the 17 treatment is a minimally invasive technique that lacks systemic toxicity; (2) there is selective 18 2 tumor destruction along with normal tissue preservation; (3) the treatment can be repeated 1 without any cumulative tissue toxicity; (4) there is little effect on the underlying functional 2 structures and there is an excellent esthetic outcome; and (5) the treatment can be applied before 3 or after any conventional treatment modality. PDT has been approved worldwide for use as a 4 clinical treatment with various photosensitizers. 4, 5) Porfimer sodium (Photofrin®) 6) is a first 5 generation photosensitizer with a long history of use that has shown it to be both reliable and 6 safe. 7) Photofrin has been licensed for use in esophageal, lung, stomach, and cervix cancer in the 7
United States, Canada, European Union, Russia, and Japan. 8) However, Photofrin-based PDT 8 for carcinoma and dysplasia in the oral cavity has yet to be approved in Japan. Photofrin is 9 activated at 630 nm, which is a wavelength that can penetrate tissues to a depth of 10 mm 9) . 10 Even though Photofrin-based PDT has been shown to be ineffective against deeper tumors, it is 11 effective for the treatment of superficial malignancies. Since almost all lesions in the oral cavity 12 can be observed macroscopically, light irradiation treatments can be carried out without having 13 to use special devices such as endoscopes. Thus, superficial malignancies and mucosal 14 dysplasia in the oral cavity are good targets for Photofrin-mediated PDT. However, few studies 15 have specifically examined using Photofrin-mediated PDT to manage carcinoma and dysplasia 16 in the oral cavity. In this study, we report the clinical outcomes and complications for 25 ; (3) tumor diameter less than 4 cm (T1 to T2) without any lymph-node or distant 13 metastases (N0, M0); (4) tumor depth less than 5 mm, as measured by magnetic resonance 14 imaging and ultrasound imaging; (5) patients with severe complications who could not tolerate 15 conventional therapy; and (6) patients who refused conventional therapy or who had previous 16 failed treatments. Patients were excluded if they had Porphyria or exhibited hypersensitivity for 17 4 porphyrin. Photofrin (Wyeth-Takeda, Tokyo, Japan) was dissolved in a 5% glucose solution and 1 administered intravenously 48 hours prior to laser irradiation at a dose of 2 mg/Kg within 2 10-minute. After PDT administration, all patients avoided direct sunlight. The excitation light 3 source used in the study was an Excimer dye laser (PDT-EDL1: Hamamatsu Photonics K.K., 4 Hamamatsu, Japan). The wavelength was 630 nm, irradiation output was 4 mJ/pulse/cm 2 , and 5 the repetition rate was 40 Hz. Light was delivered to the tumor via a 400 μm flat-tipped quartz 6 fiber. Irradiation was performed with the tip of the fiber placed approximately 1.0 cm from the 7 lesion to make 1cm 2 irradiation spot. Light doses consisted of 100 J/cm 2 11) . Irradiation times Twenty-five patients were treated by Photofrin-mediated PDT from January 2004 to 7 December 2008. Table 1 lists the demographic and histopathological characteristics of the 8 lesions in 25 patients who were treated by Photofrin-mediated PDT. The group included 12 9 males and 13 females, ranging in age from 29 to 85, with an average age of 70.8 years. A total 10 of 18 had SCC while 7 were diagnosed as epithelial dysplasia with hyperkeratosis. Out of the 25 11 patients, 5 had recurrent disease (with 4 undergoing surgery and 1 receiving radiation therapy), 12 while 20 had primary disease. 13 
Site and classification 14
A total of 30 regions were treated by PDT in the 25 patients. Locations treated included the 15 tongue (n=14), gingiva (n=6), palate (n=5), buccal mucosa (n=4) and the floor of the mouth 16 6 (n=1). In accordance with the WHO histological grading guidelines, 5 out of 7 of the epithelial 1 dysplasia patients were moderate, while 2 were classified as severe dysplasia with 2 hyperkeratosis. For the histological grading of the SCC, 17 were classified as well differentiated 3 while 1 was moderately differentiated. According to the T size classification, 9 were T1 and 10 4 were T2 (Table 1) . 5 
Treatment responses 6
Follow-up information was available for all patients. Based on the physical and histological 7 examinations, 24 out of 25 patients (96%) achieved CR, with the remaining patient classified as 8 PR. A CR was achieved by 17 out of 18 patients (94.4%) in the SCC group and in 7 out of 7 9 patients (100%) in the epithelial dysplasia group. As seen in Table 1 , the T1 palatal SCC patient 10 who only achieved PR subsequently underwent surgical resection. As of 2010, this patient has 11 remained disease-free. 12 Disease-free interval and disease-specific survival rate 13 Recurrences occurred in 3 patients (3/25: 12%) after PDT. In the SCC group, 2 out of the 18 14 patients had recurrences at 4 and 15 months. Both of these patients underwent surgical resection 15 and have remained disease-free during the subsequent follow-up periods. In the epithelial 16 dysplasia group, 1 out of 7 patients had a recurrence at 5 months after the PDT. This patient has7 been disease-free after undergoing a second Photofrin-mediated PDT procedure. Two SCC 1 patients died during the follow-up period even though they initially achieved CR. A T2 palate 2 SCC patient died 4 months after the PDT due to neck metastasis, while a T2 buccal mucosa 3 SCC patient died at 24 months after PDT due to hepatic cirrhosis. Overall, the total disease 4 specific survival rate in this study was 95.8%. 5 
Postoperative courses 6
Within 24 hours after the irradiation, swelling and edema were observed at the site and 7
continued for approximately 1 week. Severe swelling was noted more often in patients who had 8 irradiation of the tongue or buccal mucosa versus the gingiva or palate. While slight dyspnea 9 that lasted 2 to 3 days was observed in some patients who had irradiation of their tongue, none 10 of these patients required airway intervention as a result of the treatment. Postoperative pain 11 occurred 1 to 2 days after PDT, with contact and swallowing pain being the major symptom 12 seen in all patients. Systemic intraoral administration of NSAIDs was required for 3 to 4 weeks 13 post-irradiation. Some patients needed oral administration of opiates in addition to the NSAIDs. 14 Transient odynophagia made it necessary for all patients to continue on a liquid diet for 7 to 10 15 days after the treatment. Treated areas underwent surface necrosis 2 to 3 days after the 16 irradiation, with the necrosis lasting for 10 to 14 days. Complete healing occurred 4 to 6 weeks8 after PDT with little scar formation (Fig 1~4) . Direct sunlight caused a phototoxic reaction of 1 the facial edema in 2 patients. After oral administration of steroids, this reaction resolved within 2 1 week. All patients had slight skin coloration changes, although no symptoms were noted on 3 either the face or hands. This change completely disappeared within 1 year in all patients. There 4
were no persistent problems related to functional or esthetic outcomes in any of the patients. The main advantage of PDT for oral early carcinoma and dysplasia is the ability to preserve 2 normal tissue and the oral function. In the oral cavity, almost all of the lesions can be observed 3 macroscopically. Since light irradiation can be performed without the need for special devices 4 such as endoscopes, the oral cavity may be an appropriate region for PDT. Over the past 30 years, 5 the first generation photosensitizer, Porfimer sodium (Photofrin®) 6) , has been widely utilized 6 and shown to have a high level of safety. 7) However, few studies have investigated the 7 Photofrin-mediated PDT treatment outcomes for SCC and dysplasia in just the oral cavity 13-17) 8 In previous studies, treatment outcomes for oral cavity carcinoma and epithelial dysplasia have 9 been reported to vary from 83.3% to 100% [13] [14] [15] [16] [17] . In the current study, 25 patients with SCC or 10 epithelial dysplasia in the oral cavity were treated using Photofrin-mediated PDT. A single PDT 11 treatment resulted in a complete response in 24 out of 25 patients (96%). During the 24-month 12 follow-up period, recurrence occurred in 3 patients within 15 months. This result demonstrate 13 the efficacy of Photofrin-mediated PDT for both SCC and epithelial dysplasia in the oral cavity. 14 The major side effect associated with Photofrin use is its photosensitivity, which can last for up to 15 4 weeks. 5, 11) In the current study, two patients exhibited photosensitivity after discharge. Upon 16 further examination, this photosensitivity appeared to be caused by the patients wearing improper 17
clothing. In addition, although all of the patients exhibited slight pigmentation after the PDT 18 treatment, this completely disappeared without any additional persistent esthetic problems 1 within 1 year. These findings indicate that photosensitivity was not a major complication in the 2 current study. One other problem encountered during the treatment period was related to 3 postoperative swelling and pain. Postoperative swelling was observed within 24 hours after the 4 original light irradiation, with resolution occurring within 1 week. If the lesions are located at the 5 base of the tongue or on the posterior portion of the oral floor, the airways could potentially be 6 compromised. The possibility of airway obstruction needs to be taken into consideration prior to 7 treatment. Post operative pain was severe and continued to be a problem for a long time. Pain 8 relief in the current study was obtained by a 3 to 4 week systemic administration of NSAIDs 9 along with opiates, when necessary. However, the pain duration observed in the current study 10 was substantially longer than has been previously reported 18) . Light penetration depth, tumor bed 11 homogeneity, and the irradiation times have all been reported to have a major influence on 12 therapeutic effects 18, 19) . Although human tissue transmits light most effectively in the red part of 13 the visible spectrum, Photofrin only has moderate activity in the tissue because the excitation 14 wavelength (630 nm) can only penetrate tissue to a depth of 10 mm. 9) In the SCC group, we 15 observed a residual tumor on the floor of the mouth in one patient, along with recurrence on the 16 palate of another patient. The palate and the floor of the mouth have complex structures within 17 the oral cavity, with both sites having an irregular surface that makes it difficult to accurately 18 illuminate nonhomogenous structures. Therefore, an insufficient light penetration depth 1 combined with the complex structure may be responsible for the presence of residual tumor 2 cells.One patient with dysplasia of the tongue had recurrence 5 months after PDT. In this case, 3 the irradiation areas were 60×20 mm. the irradiation times this patient required over 120 min. 4 When large irradiation fields require irradiation times that are longer than 120 min, this can 5 result in a significant source of treatment error due to either patient or light source motion.
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Likewise, the reason for recurrence in patients may be due to an inaccurate light delivery that 7 occurs as a direct result of the longer required treatment times. It should be noted that patients 8 with SCC and dysplasia in the oral cavity appear to be amenable to PDT treatments. In contrast, 9 it is difficult to treat these tumors and premalignancies when using conventional therapies. 10 When employing PDT, the superficial affected areas can be easily treated without damaging the 11 surrounding normal tissues. Photofrin is a useful and reliable photosensitizer that has a long 12 history of administration worldwide. In the current study, Photofrin-mediated PDT for 13 superficial SCC and dysplasia in the oral cavity resulted in excellent outcomes. Even so, these 14 promising findings are somewhat tempered by the photosensitivity and weak tissue penetration 15 problems associated with Photofrin treatments. However, second generation photosensitizers 16 such as mTHPC 21) and mono-L-aspartylchlorin-e6 22) have been shown to not only be rapidly 17 eliminated in the body but also to have longer excitation wavelengths as compared to Photofrin.
12
Thus, use of these second-generation photosensitizers for PDT may very well to lead to better 1 results when treating early-stage SCC and dysplasia in the oral cavity. 
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